| Nov 19 |
Sangamo stock climbs 12% post-market on FDA update for ST-503
|
| Nov 19 |
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
|
| Nov 15 |
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 13 |
Q3 2024 Sangamo Therapeutics Inc Earnings Call
|
| Nov 13 |
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
|
| Nov 13 |
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Sangamo Therapeutics files for mixed shelf offering
|
| Nov 12 |
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
|
| Nov 12 |
Sangamo Therapeutics Q3 beats propel stock 5% higher
|
| Nov 12 |
Sangamo: Q3 Earnings Snapshot
|
